Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Subtyping of intraductal papillary mucinous neoplasms - pitfalls of MUC1 immunohistochemistry

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The impact of concurrent HIV and type II diabetes on immune maturation, immune regulation and immune activation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Epigenetic therapy in hematological cancers

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Mycobacterium brisbanense lung infection facilitated by steroid induced adrenal insufficiency

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The inflamed sputum in lower respiratory tract infection: l-lactate levels are correlated to neutrophil accumulation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Colorectal Cancer in Individuals With Familial Adenomatous Polyposis, Based on Analysis of the Danish Polyposis Registry

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The EFSUMB Guidelines and Recommendations for the Clinical Practice of Elastography in Non-Hepatic Applications: Update 2018

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE) Cascade Guideline

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Intraductal papillary mucinous neoplasms (IPMNs) are precursor lesions of pancreatic ductal adenocarcinoma (PDAC). Current edition of WHO Classification of Tumors of the Digestive System recognizes four different subtypes (gastric, intestinal, pancreatobiliary, and oncocytic) and recommends analysis of mucin expression (MUC1, MUC2, MUC5AC, MUC6) as well as evaluation of architectural and cell differentiation patterns for correct classification. However, there is no consensus on MUC1 expression of IPMN-lesions in the literature. Current recommendations are based on studies where antibodies against the core MUC1 protein or sialylated MUC1 (tumor associated MUC1), not the fully glycosylated MUC1 were used. We have recently reported that MUC1 is strongly expressed in both gastric and intestinal types IPMN specimens from the cystic wall, obtained by endoscopic ultrasound guided microbiopsy procedure. We have used a commercial MUC1 antibody, validated and recommended for diagnostic use, which recognizes fully glycosylated MUC1. Based on the above, we propose a revision of the WHO Classification, specifying that antibodies against tumor associated MUC1 should be used for IPMN subtyping.

OriginalsprogEngelsk
TidsskriftAPMIS - Journal of Pathology, Microbiology and Immunology
Vol/bind127
Udgave nummer1
Sider (fra-til)27-32
Antal sider6
ISSN0903-4641
DOI
StatusUdgivet - jan. 2019

ID: 55881671